| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 2.08 | -0.03 (-1.42%) | 1.20 - 3.00 | 873.6 thousand (Below Avg) |
Market data as of 3:59PM 06/18/13. Quotes are delayed by at least 15 min.
| Open | 2.12 |
|---|---|
| Previous Close | 2.11 |
| Day's Range | 2.06 - 2.16 |
| Market Cap | 173.6M |
| Avg Volume (10 Day) | 1.2M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.56 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
No news headlines available for GALE
| GALE | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | -- |
| Company | Last | Change |
|---|---|---|
| Pacific Biosciences of California Inc | 2.80 | -3.11% |
| Cempra Inc | 7.13 | +0.14% |
| Chelsea Therapeutics International Ltd | 2.45 | -5.04% |
| Neptune Technologies & Bioressources Inc | 2.98 | -0.67% |
| Corcept Therapeutics Inc | 1.83 | +1.10% |
Data is delayed by at least 15 min.